Twist Bioscience Corporation
TWSTNASDAQHealthcareDiagnostics & Research

About Twist Bioscience

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Company Information

CEOEmily Leproust
Founded2013
IPO DateOctober 31, 2018
Employees979
CountryUnited States
Fiscal YearOctober - September

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone800 719 0671
Address
681 Gateway Boulevard South San Francisco, California 94080 United States

Corporate Identifiers

CIK0001581280
CUSIP90184D100
ISINUS90184D1000
EIN46-2058888
SIC2836

Leadership Team & Key Executives

Dr. Emily Marine Leproust Ph.D.
Co-Founder, Board Chair and Chief Executive Officer
Dr. Patrick John Finn Ph.D.
President and Chief Operating Officer
Adam Laponis
Chief Financial Officer
Dennis Cho J.D.
Senior Vice President, Chief Legal Officer and Corporate Secretary
Paula Green
Senior Vice President of Human Resources
Robert F. Werner
Vice President and Chief Accounting Officer
Siyuan Chen
Chief Technology Officer
Dr. Michael Fero Ph.D.
Chief Information Officer
Nicole Moreno
Senior Vice President of Sales and Support
Jimmy Jin
Senior Vice President of Product and Marketing